Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke
Valeria Battistella, Gabriel R de Freitas, Lea Mirian Barbosa da Fonseca, Daniel Mercante, Bianca Gutfilen, Regina C S Goldenberg, Juliana Vieira Dias, Tais H Kasai-Brunswick, Eduardo Wajnberg, Paulo Henrique Rosado-de-Castro, Soniza V Alves-Leon, Rosalia Mendez-Otero, Charles Andre, Valeria Battistella, Gabriel R de Freitas, Lea Mirian Barbosa da Fonseca, Daniel Mercante, Bianca Gutfilen, Regina C S Goldenberg, Juliana Vieira Dias, Tais H Kasai-Brunswick, Eduardo Wajnberg, Paulo Henrique Rosado-de-Castro, Soniza V Alves-Leon, Rosalia Mendez-Otero, Charles Andre
Abstract
Aims: To assess the safety and feasibility of intra-arterial transplantation of autologous bone marrow mononuclear cells in patients with middle cerebral artery ischemic stroke within 90 days of symptom onset.
Patients & methods: Six patients were included in the study, and they received 1-5 × 10(8) bone marrow mononuclear cell and were evaluated using blood tests, neurological and imaging examination before treatment, and 1, 3, 7, 30, 60, 90, 120 and 180 days after transplantation. Scintigraphies were carried out 2 and 24 h after the procedure to analyze the biodistribution of labeled cells. Electroencephalogram was conducted within 7 days after transplantation.
Results: No patients exhibited any complication or adverse events during the procedure. There was no worsening in the neurological scales until the end of the follow-up.
Conclusion: Intra-arterial bone marrow mononuclear cell transplantation is feasible and safe in patients with nonacute ischemic strokes of the middle cerebral artery. Further studies are required to evaluate the efficacy of this therapy.
Source: PubMed